Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for prevention of radiotherapy-induced toxicity in prostate cancer
ACTRN12612000101886Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of famotidine in prostate cancer (PCa) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Gastrointestinal acute toxicity and Genitourinary acute toxicity. Started Apr 2012; status: completed.
02
Drugs
famotidine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12612000101886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000101886.